Decoding health through molecular insight.

Aitiologic is a precision medicine startup providing multi-modal liquid biopsy solutions for early disease detection and targeted therapy.

Platform

Technology foundation and first applications.

We are building the first multi-modal liquid biopsy platform to decode genomic, epigenomic, and fragmentomic cfDNA signals at single-molecule resolution from a simple blood draw.

Technology

Aitios® Platform

Foundational multi-modal liquid biopsy platform for tissue-resolved cfDNA signal interpretation.

Explore

Application

Aitios® NIPPT

First-trimester Non-Invasive Prenatal and Preeclampsia Testing for early risk stratification.

Explore
Updates

Latest news and events.

White Paper

November 2026

Preeclampsia: an asymmetric investment opportunity?

Preeclampsia affects nearly 10% of US births and costs more than $28 billion for each year's cases. It can, however, be prevented. Yet it has no approved disease-modifying therapy and no recommended early risk screen.

Read white paper

AJOG Global Reports

June 2026

First-Trimester Multi-modal cfDNA Analysis for Prediction of Preterm and Term Preeclampsia

First-trimester multi-modal, tissue-resolved cfDNA analysis enables early risk stratification across the full clinical spectrum of preeclampsia from a single routine blood sample.

Read in AJOG Global Reports

Upcoming event

J.P. Morgan - The Munich LifeScience Forum 2026

Sep 16, 2026 | Munich, Germany

Meet us at J.P. Morgan's Munich LifeScience Forum in Munich for conversations across biotechnology, life science company building, investment, and translational innovation.

Meet us

Sep 15, 2026

Aitiologic Raises €6.4 Million in Oversubscribed Seed Financing to Advance Tissue-Resolved Liquid Biopsy Platform and Preeclampsia Lead Program

The financing, co-led by Heal Capital and Ananda Impact Ventures, will advance the Aitios® Platform and its lead program for first-trimester preeclampsia risk assessment.

Read on GlobeNewswire

Dec 6, 2025

Aitiologic Takes on Preeclampsia: Preparing for Large-Scale Validation after Presentation of Feasibility Study at FMF Conference in London

Aitiologic's Chief Medical Officer, Dr. Rebecca Ertl, presented the first feasibility results of the Aitios® platform for tissue-specific liquid biopsy to over 1,500 clinicians and researchers.

Open article

Network & Development Partners

Supported by leading funding, innovation, and technology partners.